Aprea Therapeutics, Inc.(APRE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

APRE Aprea Therapeutics, Inc.

Not Yet Opened 12-10 16:00:00 EST

0.9122

-0.0155

-1.67%

盘后0.9200

+0.0078+0.86%

16:30 EST

High1.00	Low0.9010	Vol108.84K
Open1.00	D1 Closing0.9277	Amplitude10.67%
Mkt Cap5.76M	Tradable Cap4.19M	Total Shares6.31M
T/O102.38K	T/O Rate2.37%	Tradable Shares4.59M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"APRE","market":"US","secType":"STK","nameCN":"Aprea Therapeutics, Inc.","latestPrice":0.9122,"timestamp":1765400400000,"preClose":0.9277,"halted":0,"volume":108838,"hourTrading":{"tag":"盘后","latestPrice":0.92,"preClose":0.9122,"latestTime":"16:30 EST","volume":530,"amount":488.4244,"timestamp":1765402251946},"delay":0,"floatShares":4588277,"shares":6310673,"eps":-2.136425,"marketStatus":"Not Yet Opened","change":-0.0155,"latestTime":"12-10 16:00:00 EST","open":1,"high":1,"low":0.901,"amount":102378.5082352,"amplitude":0.106716,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-2.136425,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765443600000},"marketStatusCode":0,"adr":0,"listingDate":1570075200000,"exchange":"NASDAQ","adjPreClose":0.9277,"postHourTrading":{"tag":"盘后","latestPrice":0.92,"preClose":0.9122,"latestTime":"16:30 EST","volume":530,"amount":488.4244,"timestamp":1765402251946},"volumeRatio":0.949351,"impliedVol":4.309,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/APRE","defaultTab":"news","newsList":[{"id":"2590341562","title":"Aprea Therapeutics Inc - Net Proceeds Expected to Fund Aprea Into 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2590341562","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590341562?lang=en_us&edition=fundamental","pubTime":"2025-12-09 21:30","pubTimestamp":1765287002,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nTUA91RFGD:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["APRE","BK4139"],"gpt_icon":0},{"id":"2590341337","title":"Press Release: Aprea Therapeutics Announces $3.1 Million Private Placement Priced At-The-Market Under Nasdaq Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2590341337","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590341337?lang=en_us&edition=fundamental","pubTime":"2025-12-09 21:30","pubTimestamp":1765287000,"startTime":"0","endTime":"0","summary":"Financing from new and existing healthcare focused investors. The proceeds are expected to extend the Company's cash runway into Q1 2027, with potential inflection points anticipated in its clinical programs during that period. The offer and sale of the foregoing securities are being made in a private placement under Section 4 of the Securities Act of 1933, as amended , and/or Regulation D promulgated thereunder, and the securities have not been registered under the Securities Act or applicable state securities laws. Accordingly, the securities may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. The Company has agreed to file a registration statement with the Securities and Exchange Commission registering the resale of the securities purchased in the private placement.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","APRE","LENZ","NQmain","BK4007"],"gpt_icon":0},{"id":"2582745603","title":"Aprea Therapeutics Reports Continued Clinical Progress and Extends Cash Runway Into Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2582745603","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582745603?lang=en_us&edition=fundamental","pubTime":"2025-11-12 21:36","pubTimestamp":1762954568,"startTime":"0","endTime":"0","summary":"Aprea Therapeutics Inc. announced its financial results for the third quarter ended September 30, 2025, and provided a business update. The company reported continued progress in its WEE1 and ATR inhibitor programs and stated it has a cash runway into the fourth quarter of 2026. In the ongoing Phase 1 ACESOT-1051 dose-escalation trial for APR-1051, a WEE1 kinase inhibitor, 3 out of 4 patients at Dose Level 6  achieved stable disease, according to RECIST v1.1, among heavily pretreated patients with gastrointestinal and gynecologic malignancies. The company has recently advanced to the 150 mg once daily cohort as dose escalation continues. For ATRN-119, an ATR kinase inhibitor, the recommended Phase 2 dose  of 1,100 mg once daily was identified in the ABOYA-119 dose-escalation study. Aprea is considering potential combination strategies for ATRN-119, including with radiation or checkpoint inhibitors. Posters with updated data for both APR-1051 and ATRN-119 were presented at the AACR-NCI-","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL9GbWgf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APRE","BK4139"],"gpt_icon":0},{"id":"2582537453","title":"Aprea Therapeutics Advances WEE1 Inhibitor APR-1051 in Phase 1 Trial for Hard-to-Treat Cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2582537453","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582537453?lang=en_us&edition=fundamental","pubTime":"2025-11-12 21:30","pubTimestamp":1762954230,"startTime":"0","endTime":"0","summary":"Aprea Therapeutics Inc. has announced updates on its ongoing clinical trials for two investigational cancer therapies, APR-1051 and ATRN-119. In the Phase 1 ACESOT-1051 dose-escalation trial of APR-1051, a WEE1 kinase inhibitor, 3 out of 4 patients at the 100 mg once daily dose level achieved stable disease in heavily pretreated gastrointestinal and gynecologic malignancies. Dose escalation has continued to the 150 mg once daily cohort. For ATRN-119, an ATR kinase inhibitor, the recommended Phase 2 dose  has been identified as 1,100 mg once daily in the ABOYA-119 dose-escalation study. Results from these studies were presented in posters at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics on October 24, 2025. Future studies may evaluate APR-1051 in combination with checkpoint inhibitors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely inform","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL8Bp6m9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU2210150020.SGD","BK4112","LU2095319765.USD","IE00B3QW5Z07.USD","LU0314104364.USD","IE00BGHQF748.EUR","BK4585","APRE","IE00B64PRP62.GBP","LU2210149790.SGD","NDAQ","BK4588","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2582374879","title":"Aprea Therapeutics Inc - Has Cash Runway Into Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2582374879","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582374879?lang=en_us&edition=fundamental","pubTime":"2025-11-12 21:30","pubTimestamp":1762954202,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nTUA6SWV5W:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","APRE"],"gpt_icon":0},{"id":"2582374883","title":"Aprea Therapeutics Q3 Net Income USD -3 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2582374883","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582374883?lang=en_us&edition=fundamental","pubTime":"2025-11-12 21:30","pubTimestamp":1762954202,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nPLX5D5027:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","APRE"],"gpt_icon":0},{"id":"2577751674","title":"BRIEF-Aprea Sees Early Activity in APR-1051 Wee1 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2577751674","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577751674?lang=en_us&edition=fundamental","pubTime":"2025-10-24 20:42","pubTimestamp":1761309742,"startTime":"0","endTime":"0","summary":"BRIEF-Aprea Sees Early Activity in APR-1051 Wee1 TrialOct 24 (Reuters) - Aprea Therapeutics Inc APRE.O:APREA THERAPEUTICS PROVIDES CLINICAL UPDATE FROM ACESOT-1051 TRIAL SHOWING EARLY SIGNALS OF ACTIV","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251024:nTUA59XSC8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APRE","BK4139"],"gpt_icon":0},{"id":"2577851655","title":"Aprea Therapeutics Provides Clinical Update From Acesot-1051 Trial Showing Early Signals of Activity for Wee1 Kinase Inhibitor Apr-1051","url":"https://stock-news.laohu8.com/highlight/detail?id=2577851655","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577851655?lang=en_us&edition=fundamental","pubTime":"2025-10-24 20:30","pubTimestamp":1761309000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251024:nTUA59XSC8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","APRE"],"gpt_icon":0},{"id":"2577695516","title":"Aprea Therapeutics Inc - No Dose Limiting Toxicities or Unexpected Safety Issues Reported","url":"https://stock-news.laohu8.com/highlight/detail?id=2577695516","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577695516?lang=en_us&edition=fundamental","pubTime":"2025-10-24 20:30","pubTimestamp":1761309000,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251024:nTUA59XSC8:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","APRE"],"gpt_icon":0},{"id":"2577612516","title":"Aprea Therapeutics Inc - Dose Escalation Continues With 150 Mg Cohort Enrollment","url":"https://stock-news.laohu8.com/highlight/detail?id=2577612516","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577612516?lang=en_us&edition=fundamental","pubTime":"2025-10-24 20:30","pubTimestamp":1761309000,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251024:nTUA59XSC8:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","APRE"],"gpt_icon":0},{"id":"2575729741","title":"Aprea Therapeutics Announces Presentations at Eortc-Nci-Aacr International Conference on Molecular Targets and Cancer Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2575729741","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575729741?lang=en_us&edition=fundamental","pubTime":"2025-10-14 20:00","pubTimestamp":1760443205,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251014:nTUAFRMSK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["APRE","BK4139"],"gpt_icon":0},{"id":"2558647252","title":"Aprea Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2558647252","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558647252?lang=en_us&edition=fundamental","pubTime":"2025-08-12 21:31","pubTimestamp":1755005510,"startTime":"0","endTime":"0","summary":"Aprea Therapeutics Inc reports results for the quarter ended June 30 - Earnings SummaryAprea Therapeutics Inc APRE.OQ reported a quarterly adjusted loss of 53 cents per share for the quarter ended Jun","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250812:nL8N3U414K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APRE"],"gpt_icon":0},{"id":"2558082644","title":"Aprea Therapeutics Reports Q2 2025 Results: Net Loss Narrows to $3.2M, EPS Improves to $0.53 from $0.58","url":"https://stock-news.laohu8.com/highlight/detail?id=2558082644","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558082644?lang=en_us&edition=fundamental","pubTime":"2025-08-12 20:06","pubTimestamp":1755000380,"startTime":"0","endTime":"0","summary":"Aprea Therapeutics Inc. , a clinical-stage biopharmaceutical company, reported its financial results for the second quarter ended June 30, 2025. The company posted a net loss of $3.2 million, or $0.53 per basic share, compared to a net loss of $3.5 million, or $0.58 per basic share, in the same period of 2024. Operating losses decreased to $3.4 million from $3.8 million in the second quarter of 2024. Research and Development expenses were down to $1.9 million from $2.6 million in the previous year, attributed primarily to reduced study start-up activities and personnel costs. General and Administrative expenses also saw a reduction, amounting to $1.6 million compared to $1.9 million in the prior year, mainly due to lower professional fees and personnel costs. As of June 30, 2025, Aprea reported $16.5 million in cash and cash equivalents. The company highlighted early evidence of disease control in its ongoing Phase 1 ACESOT-1051 trial, with three patients achieving stable disease in th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250812:nNDL2WFnGv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APRE"],"gpt_icon":0},{"id":"2558264489","title":"Aprea Therapeutics Q2 EPS USD -0.53","url":"https://stock-news.laohu8.com/highlight/detail?id=2558264489","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558264489?lang=en_us&edition=fundamental","pubTime":"2025-08-12 20:00","pubTimestamp":1755000005,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250812:nPLXFDBC69:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["APRE","BK4139"],"gpt_icon":0},{"id":"2558579913","title":"Aprea Therapeutics Inc  expected to post a loss of 74 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2558579913","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558579913?lang=en_us&edition=fundamental","pubTime":"2025-08-09 01:44","pubTimestamp":1754675058,"startTime":"0","endTime":"0","summary":"Aprea Therapeutics Inc  expected to post a loss of74cents a share - Earnings Preview Aprea Therapeutics Inc APRE.OQ APRE.O is expected to  show a fall in quarterly revenue when it reports  results on ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250808:nL8N3U034K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APRE"],"gpt_icon":0},{"id":"2546241017","title":"Aprea Says APR-1051 Shows Early Disease Control in HPV-Positive Head and Neck Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2546241017","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546241017?lang=en_us&edition=fundamental","pubTime":"2025-06-25 23:16","pubTimestamp":1750864583,"startTime":"0","endTime":"0","summary":"Aprea Therapeutics  said Wednesday that initial data from a phase 1 trial showed that APR-1051 achieved \"early disease control\" with a 5% tumor reduction at the first radiographic assessment of a patient with advanced human papillomavirus-positive head and neck squamous cell carcinoma, or HNSCC.The investigational therapy was also well-tolerated, with no dose-limiting toxicities, the company said, adding the trial is actively enrolling more HPV+ patients and moving into higher dose levels.Aprea also said preclinical data generated through an ongoing research collaboration with MD Anderson Cancer Center showed that APR-1051 has potential both as a standalone therapy and in combination with immunotherapy for biomarker-driven treatment of HPV+ HNSCC.APR-1051 showed \"robust\" antiproliferative effects across a wide range of human and mouse head and neck cancer cell lines, including HPV+ subtypes, according to the company. When combined with anti-PD-1 immunotherapies, APR-1051 demonstrated \"","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","APRE"],"gpt_icon":0},{"id":"2546248481","title":"BRIEF-Aprea Reports Promising Early Data for WEE1 Inhibitor in HPV+ HNSCC with MD Anderson","url":"https://stock-news.laohu8.com/highlight/detail?id=2546248481","media":"Reuters","labels":["corporation","dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546248481?lang=en_us&edition=fundamental","pubTime":"2025-06-25 21:03","pubTimestamp":1750856627,"startTime":"0","endTime":"0","summary":"BRIEF-Aprea Reports Promising Early Data for WEE1 Inhibitor in HPV+ HNSCC with MD AndersonJune 25 (Reuters) - Aprea Therapeutics Inc APRE.O:APREA REPORTS ANTI-PROLIFERATIVE RESULTS AND PROMISING EARLY","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250625:nTUA42LKT3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"BRIEF-Aprea Reports Promising Early Data for WEE1 Inhibitor in HPV+ HNSCC with MD Anderson","news_tag":"corporation,dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","APRE"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.aprea.com","stockEarnings":[{"period":"1week","weight":-0.1144},{"period":"1month","weight":-0.2817},{"period":"3month","weight":-0.419},{"period":"6month","weight":-0.5043},{"period":"1year","weight":-0.7384},{"period":"ytd","weight":-0.7227}],"compareEarnings":[{"period":"1week","weight":0.0054},{"period":"1month","weight":0.009},{"period":"3month","weight":0.0455},{"period":"6month","weight":0.1517},{"period":"1year","weight":0.1406},{"period":"ytd","weight":0.1732}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors, ovarian, breast, and prostate cancers. The company is also developing ATRN-1051, ATRN-354, and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.081534},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.064106},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.101733},{"month":4,"riseRate":0,"avgChangeRate":-0.145433},{"month":5,"riseRate":0,"avgChangeRate":-0.129229},{"month":6,"riseRate":0.333333,"avgChangeRate":0.023066},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.044399},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.005221},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.052829},{"month":10,"riseRate":0.333333,"avgChangeRate":0.013865},{"month":11,"riseRate":0.428571,"avgChangeRate":-0.091344},{"month":12,"riseRate":0.428571,"avgChangeRate":-0.046421}],"exchange":"NASDAQ","name":"Aprea Therapeutics, Inc.","nameEN":"Aprea Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Aprea Therapeutics, Inc.(APRE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Aprea Therapeutics, Inc.(APRE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Aprea Therapeutics, Inc.,APRE,Aprea Therapeutics, Inc.股票,Aprea Therapeutics, Inc.股票老虎,Aprea Therapeutics, Inc.股票老虎国际,Aprea Therapeutics, Inc.行情,Aprea Therapeutics, Inc.股票行情,Aprea Therapeutics, Inc.股价,Aprea Therapeutics, Inc.股市,Aprea Therapeutics, Inc.股票价格,Aprea Therapeutics, Inc.股票交易,Aprea Therapeutics, Inc.股票购买,Aprea Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Aprea Therapeutics, Inc.(APRE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Aprea Therapeutics, Inc.(APRE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}